Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Our instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats.

The company’s innovative and patent-pending time of flight mass spec technology dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems currently deployed for biodefense applications. Our instrument’s high sensitivity enables fully-automated and near real-time identification of bio-threats in operational environments.

Our approach leverages decades of development surrounding the molecular basis of pathogenic organisms and biological toxins.

The U.S. Department of Defense is funding the development of Zeteo’s miniaturized, low-cost, low-power mass spectrometer technology for the identification of aerosolized bio-threats in near real-time. Our current application focus is critical infrastructure protection.

Two billion people are infected with TB globally and it is the leading cause of death by infectious disease.

World Health Organization

Preliminary measurements demonstrate that we can rapidly and non-invasively screen populations to find individuals likely to have tuberculosis (TB), and at a cost of pennies per person.

Because of the high prevalence of TB globally, the emergence of highly drug-resistance strains, and the lack of an effective vaccine, mass patient screening, or “active case finding,” is perhaps the most effective near-term strategy to control the TB epidemic.

Zeteo’s innovative and patent-pending time-of-flight mass spec technology dramatically lowers instrument cost and size relative to the MALDI instruments used globally in the clinical diagnostics market today. Our instrument’s high sensitivity enables near real-time screening for disease at the point-of-care, without culturing or other means of signal amplification.

Zeteo Tech is currently supported by the Bill and Melinda Gates Foundation to accelerate the development and translation of innovative new products for patient screening based on respired air.